Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma

Allergic Asthma Clinical Trial

Official title:

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00980707
• Other study ID #: AI-005 versican
• Status: Completed
• Phase: Phase 4
• First received: September 17, 2009
• Last updated: January 18, 2012
• Start date: August 2009
• Est. completion date: November 2010

Study information

• Verified date: January 2012
• Source: Associated Scientists to Help Minimize Allergies
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the role of versican and hyaluronan measurements in induced sputum as biomarkers of asthma. Enroll 10 subjects with mild persistent asthma who are not receiving treatment with a controller therapy.

Description:

We will compare spirometry, eNO and sputum measurements of versican and hyaluronan before and after treatment with fluticasone 220 ug/bid.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Allergic asthma defined as a positive methacholine challenge

Exclusion Criteria:

• Non-atopic patients

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Allergic Asthma
• Asthma

Intervention

Drug:
• Inhaled corticosteroid (fluticasone)
inhaled fluticasone 220 ug/bid

Locations

Country	Name	City	State
United States	Associated Scientists to Help Minimize Allergies	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
Associated Scientists to Help Minimize Allergies	Benaroya Research Institute, GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare hyaluronan and versican in asthmatics versus atopic non-asthmatics.		1 year	No